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Multiple displacement amplification (MDA) is widely used in whole-genome/transcriptome amplification. However, template-independent amplification (TIA) in MDA is a commonly observed phenomenon, particularly when using high concentrations of random hexamer primers and extended
incubation times. Here, we demonstrate that the use of random pentamer primers with 5´ ends
blocked by a C18 spacer results in MDA solely in a template-dependent manner, a technique we
have named tdMDA. Together with an optimized procedure for the removal of residual genomic
DNA during RNA extraction, tdMDA was used to profile circulating RNA from 0.2 mL of patient
sera. In comparison to regular MDA, tdMDA demonstrated a lack of quantifiable DNA amplification
in the negative control, a remarkable reduction of unmapped reads from Illumina sequencing (7 ±
10.9% versus 58.6 ± 39%, P = 0.006), and increased mapping rates of the serum transcriptome
(26.9 ± 7.9% versus 5.8 ± 8.2%, P = 3.8 × 10 -4). Transcriptome profiles could be used to separate
patients with chronic hepatitis C virus (HCV) infection from those with HCV-associated hepatocellular carcinoma (HCC). We conclude that tdMDA should facilitate RNA-based liquid biopsy, as well
as other genome studies with biological specimens having ultralow amounts of genetic material.
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Multiple displacement amplification
(MDA) is a method of isothermal
DNA amplification frequently applied
to whole-genome amplification (1).
MDA typically utilizes phi29 DNA
polymerase, which shows exceptional
processivity along with strong stranddisplacement and exonuclease activity.
As a consequence, MDA outperforms
PCR-based approaches in terms
of template coverage and amplification fidelity (2). In addition, stranddisplacement amplification results in
a hyper-branched product with a high
molecular weight (≥10 kb), which is

ideal for library construction in nextgeneration sequencing (NGS). For
these reasons, MDA, in combination
with NGS, has become a gold standard
method in genomic research (3–5). A
long-standing issue in MDA is templateindependent amplification (TIA), particularly when amplifying ultralow concentrations of templates that require high
concentrations of random hexamer
primers and an extended incubation
period (1). Positive amplification due
to TIA in negative controls not only
compromises confidence in experimental results, but, more impor-

tantly, generates junk DNA (1). Even
when using well-optimized MDA
protocols, junk DNA may compose up
to 70% of the product (1,6,7). Elimination of junk DNA has attracted
significant investigation, including
the use of dimethyl sulfoxide (DMSO)
(8,9), T4 gene 32 (9), trehalose (10),
single-stranded DNA binding protein
(SSB) (11), random hexamer primers
containing an internal C3 spacer (12),
RNA primer (13), chimeric DNA-RNA
primer (14), modulation of incubation
temperature (15), and the reduction of
reaction volume (16). However, these

METHOD SUMMARY
Random pentamer primers blocked at the 5´ end with a C18 spacer were shown to eliminate template-independent
amplification, a major problem in multiple displacement amplification.
Vol. 63 | No. 1 | 2017
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Sequence (5’→ 3’)

MDA yield (µg)

1

2

3

4

Figure 1. List of primers tested in multiple displacement amplification (MDA). Group 1 primers have phosphorothioate bonds placed at different positions
to test the minimum lengths of primers capable of initiating DNA polymerization. Group 2 primers are modified internally with a C3 spacer to minimize
self-priming. Group 3 primers are the group 2 primers modified with the inclusion of locked nucleic acid (LNA) to stabilize the binding between primers
and templates. Groups 4 and 5 are constrained primers and RNA primers (with or without a C3 spacer), respectively. Random primers blocked at the 5´
end are designated as group 6 (hexamer) or group 7 (pentamer) primers. In these two groups of primers, the blockage at the 5´ end was tested using different modifications, including inverted, 2´,3´dideoxy-dT base (5´ inverted ddT), dSpacer, C3 spacer, C9 spacer, C18 spacer, amino modifier C6 (AmMC6)
or alkyne. Degenerate bases are indicated using standard International Union of Pure and Applied Chemistry (IUPAC) codes. Each primer was tested in
triplicate at a concentration of 50 µM in the standard MDA protocol with (blue) or without (red) template [1 ng of the hepatitis C virus (HCV) plasmid].
The MDA reaction with the group 7 primers was incubated at 28°C, while the other groups of primers were amplified at 30°C. The error bars indicate SD.

options have not been widely adopted.
Increasing the amount of template (≥10
ng) and using a short incubation time, as
recommended in many commercial kits
such as the REPLI-g kits from QIAGEN,
is a common option to minimize TIA, yet
such an amount (10 ng) is not always
available in many biological scenarios.
Here, we have developed a robust MDA
protocol that is free of TIA through the
use of 5´ end-blocked random pentamer
primers. Isothermal amplification occurs
solely in a template-dependent manner,
which we have named tdMDA. The
potential of tdMDA has been demonstrated by an efficient profiling of human
circulating RNA, a biological source
Vol. 63 | No. 1 | 2017

notorious for its ultralow concentration
and complex heterogeneity (17).

Materials and methods
Patient samples
A total of 30 serum samples were used
in the current study. Of these, 20 were
from a completed study (18), and 3
samples from blood donors were used
to optimize the experimental protocols
for RNA extraction, genomic DNA
removal, and tdMDA. The remaining
seven samples were collected from
patients at the Saint Louis University
Hospital. Three patients had chronic
HCV infection, and the other four were

22

diagnosed with HCV-associated hepatocellular carcinoma (HCC) by computed
tomography (CT), serum a fetoprotein
(AFP) measurement, and histological
examination. These samples were used
to test the feasibility of circulating RNA
profiling through the use of tdMDA.

Ethics statement
For the collection of serum samples,
written informed consent was obtained
from each patient and was approved by
the local Institutional Review Board in
the parental studies (19). The research
protocol for the collection and use of
patient samples was reviewed and
approved by the Saint Louis University
www.BioTechniques.com
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Institutional Review Board (IRB protocol:
SLU15565).

Standard MDA protocol
In order to facilitate experimental optimization, we defined a standard MDA
protocol with a reaction volume of 40 µL
and consisting of phi29 DNA polymerase
and its corresponding buffer, 1 mM of
dNTPs, and 2 µM or 50 µM of random
exonuclease-resistant primers. A recombinant 12-kb plasmid (HCV plasmid)
containing a 9-kb HCV genotype 1a
genome from our previous study (20)
was used as a positive control. The
reaction was incubated at 30°C for 16
h, followed by heat-inactivation at 65°C
for 10 min. In addition to visualization
on a 0.8% agarose gel, MDA yield was
quantitated by the Quant-iT PicoGreen
dsDNA Assay kit (QIAGEN, Valencia, CA)
after purification using the QIAamp DNA
mini kit. Due to the extreme sensitivity of
the techniques (5), all MDA experiments
were performed in strict adherence to
the recommendations of Champlot et
al. to avoid possible contamination (21).

Elimination of TIA in MDA
The extreme sensitivity of MDA also
causes confusion between TIA and
reagent contamination, wherein the
latter is caused by trace amounts of
bacterial or other microbial genomes left
during manufacture. Without additional
experimentation, it was difficult to clarify
if the positive amplification in negative
controls resulted from TIA or reagent
contamination. Therefore, a multi-step
strategy was applied to eliminate TIA
in MDA. First, using the standard MDA
protocol, we evaluated the purity of
phi29 DNA polymerases from various
vendors, including Lucigen (Middleton,
WI), Epicentre (Madison, WI), Thermo
Scientific (St. Louis, MO), and New
England Biolabs (Ipswich, MA). Decontamination through UV irradiation as
described by Woyke et al. was also
adopted for the reagents, including
phi29 D N A po l y m e ra se, dN T Ps,
and primers (8). The procedure was
conducted with the Stratagene Stratalinker 2400 UV Crosslinker (Agilent
Technologies, Santa Clara, CA). Next,
using the standard MDA protocol with
reagents that were free of contamination,
elimination of TIA was evaluated by the
use additives such as DMSO (0.5~5%)

(Sigma-Aldrich, St. Louis, MO), Escherichia coli SSB (50~300 µg/mL) (New
England Biolabs), and Fc400 (4~64
mg/mL) (Sigma-Aldrich) to emulate a
crowded intracellular environment (22).
The incubation temperature was tested
from 25°C to 35°C.
Finally, we focused on primer
optimization by designing a total of 36
different types of primers that could
be categorized into 7 groups (Figure
1). Primers containing locked nucleic
acid (LNA) were synthesized by Exiqon
(Woburn, MA). All remaining primers

were purchased from Integrated DNA
Technologies (IDT, Coralville, IA). Each
primer was tested in triplicate at 50 µM,
a typical concentration used in MDA
(1,2).

Serum RNA extraction, genomic DNA
removal, and real-time RT-tdMDA
Total RNA was extracted from 200 µL
serum using the miRNeasy Serum/
Plasma kit (QIAGEN) and then eluted
into 14 µL water. E x tracted RNA
was quantitated using the Quant-iT
RiboGreen RNA kit (Life Technologies,

Micro RNA, small RNA, mRNA, FFPE RNA, Total RNA, ribo-depleted RN
lnRNA, snRNA, Micro RNA, small RNA, mRNA, FFPE RNA, Total RNA,
ribo-depleted RNA, lnRNA, snRNA, Micro RNA, small RNA, mRNA, FFPE
RNA, Total RNA, ribo-depleted RNA, lnRNA, snRNA, Micro RNA, small RN
mRNA, FFPE RNA, Total RNA, ribo-depleted RNA, lnRNA, snRNA, Micro
RNA, small RNA, mRNA, FFPE RNA, Total RNA, ribo-depleted RNA, lnRN
snRNA, Micro RNA, small RNA, mRNA, FFPE RNA, Total RNA, ribo-deple
ed RNA, lnRNA, snRNA, Micro RNA, small RNA, mRNA, FFPE RNA, Tota
RNA, ribo-depleted RNA, lnRNA, snRNA, Micro RNA, small RNA, mRNA,
FFPE RNA, Total RNA, ribo-depleted RNA, lnRNA, snRNA, Micro RNA, sm
RNA, mRNA, FFPE RNA, Total RNA, ribo-depleted RNA, lnRNA, snRNA,
Micro RNA, small RNA, mRNA, FFPE RNA, Total RNA, ribo-depleted RN
lnRNA, snRNA, Micro RNA, small RNA, mRNA, FFPE RNA, Total RNA,
ribo-depleted RNA, lnRNA, snRNA, Micro RNA, small RNA, mRNA, FFPE
RNA, Total RNA, ribo-depleted RNA, lnRNA, snRNA, Micro RNA, small RN
mRNA, FFPE RNA, Total RNA, ribo-depleted RNA, lnRNA, snRNA, Micro
RNA, small RNA, mRNA, FFPE RNA, Total RNA, ribo-depleted RNA, lnRN
snRNA, Micro RNA, small RNA, mRNA, FFPE RNA, Total RNA, ribo-deple
ed RNA, lnRNA, snRNA, Micro RNA, small RNA, mRNA, FFPE RNA, Tota
RNA, ribo-depleted RNA, lnRNA, snRNA, Micro RNA, small RNA, mRNA,
FFPE RNA, Total RNA, ribo-depleted RNA, lnRNA, snRNA, Micro RNA, sm
RNA, mRNA, FFPE RNA, Total RNA, ribo-depleted RNA, lnRNA, Total RN
Micro RNA, small RNA, mRNA, FFPE RNA, Total RNA, ribo-depleted RN
mRNA, FFPE RNA, Total RNA, ribo-depleted RNA, lnRNA, snRNA, Micro
RNA, small RNA, mRNA, FFPE RNA, Total RNA, ribo-depleted RNA, lnRN
snRNA, Micro RNA, small RNA, mRNA, FFPE RNA, Total RNA, ribo-deple
ed RNA, lnRNA, snRNA, Micro RNA, small RNA, mRNA, FFPE RNA, Tota
RNA, ribo-depleted RNA, lnRNA, snRNA, Micro RNA, small RNA, mRNA,
Micro RNA, small RNA, mRNA, FFPE RNA, Total RNA, ribo-depleted RN
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Non‐dilution
Estimated cDNA input:
Sample #1: 1 ng
Sample #2: 1.56 ng
Sample #3: 2.71 ng

1:10 dilution

1:100 dilution
Negative control
(H2O)

Incubation time (hours)
Figure 2. Real-time reverse transcription–template dependent multiple displacement amplification (RT-tdMDA) using three hepatitis C virus (HCV) patient serum samples and a negative
control (H 2 O). These samples covered the range of the RNA yield extracted from 200 µL serum
(7.5–19.2 ng), as quantitated in the final 14 mL of elution by the QIAGEN miRNA kit prior to
HL-DNase digestion. An aliquot of 10.6 mL RNA was used for RT in a reaction containing 200
U SuperScript III, 80 mM 5´-end-blocked random pentamer primer (5´-/iSpC3/NNN*N*N-3´;
asterisks denote phosphorothioate bonds), and 2 mM dNTPs in a 20-mL volume. An aliquot
of 4 mL of the RT reaction was used in a 40-mL tdMDA reaction containing 300 U phi29 DNA
polymerase (Epicentre), 80 mM primer, and 0.1× SYBR Green I (Thermo Fisher Scientific).
The reaction was incubated at 28°C for 24 h on the ABI TaqMan 7500, in which fluorescent
intensities were monitored through the SYBR Green channel. Estimated amount of cDNA input
in tdMDA = [10.6 / (14 + 0.5 (HL-DNase) + 1.4 (buffer)] × [total RNA amount] × 0.2. Templateindependent amplification was completely inhibited, as indicated by the negative control.

St. Louis, MO) on a fluorescence
microplate reader. Five options were
tested to remove residual genomic
DNA during RNA extraction (Supplementary Table S1) using a 12-kb HCV
plasmid as a spike-in DNA that was
added to serum prior to RNA extraction
(1 µg HCV plasmid per 200 µL serum).
Using purified RNA as the template, a
30-cycle HCV non-structural gene 3
(NS3)–specific PCR was conducted
to determine the efficiency of genomic
DNA removal.
Purified RNA (9.4 µL) was reverse
transcr ibe d in a 20 µ L re action
consisting of 1× SuperScript III buffer
(Life Technologies), 10 mM DT T, 2
mM dNTPs, 20 U RNasein RNase
Inhibitor (Promega, Madison, WI), 200
U SuperScript III reverse transcriptase
and 80 µM primers. The reaction was
incubated at 37°C for 30 min, 50°C for
30 min, and then inactivated at 70°C
for 15 min. An aliquot of 4 µL of this
reverse transcription (RT ) reaction
served as the template in the subsequent MDA. Both RT and MDA used the
same random primer capable of elimiVol. 63 | No. 1 | 2017

nating TIA. Using three serum samples
with different RNA concentrations, we
conducted real-time RT-tdMDA with
0.1× SYBR Green I ( Thermo Fisher
Scientific) included in the tdMDA step.
The reaction was incubated at 28°C
for 24 h on the ABI 7500 Real-Time
PCR System (Applied Biosystems,
Foster City, CA). The resulting curves
of fluorescent intensity were used to
determine an optimal incubation time
for RT-tdMDA applied to HCV and HCC
patient samples.

Illumina sequencing
The optimized procedures from RNA
extraction and purification were applied
to serum samples from seven HCV
and HCC patients. The cDNA from
the RT reaction was amplified by both
tdMDA and the regular MDA protocol
using random hexamer primers (primer
6NS2 listed in Figure 1). Based on the
product size (~20 kb), the purified
RT-MDA product was diluted to 0.4
ng/µL and enzymatically sheared by
incubating the DNA at 55°C for 5 min
using the Nextera X T transposome

24

from the Nex tera X T DNA Sample
Preparation kit (Illumina, San Diego,
CA), which added adapter sequences
simultaneously. Fragmented DNA was
amplified with 12 cycles of PCR using
the Index 1 and Index 2 primers from
Illumina, followed by purification and
size selection using AMPure XP beads
(Beckman Coulter, Beverly, MA). Sizeselected libraries were normalized
using the normalization beads from
Illumina. In this step, the quantity of
each library was normalized to ensure
equal representation in the pooled
sample. An aliquot of 2 µL normalized
and pooled library was added to 998
µL pre-chilled hybridization buf fer,
denatured at 98°C for 2 min, and then
sequenced on the Illumina NextSeq 500
Sequencing platform (1 × 250-bp single
reads and mid-output) at MOgene (St.
Louis, MO).

Data analysis
Raw sequence reads in fastq format
were first filtered in PRINSEQ (v0.19.5)
for quality control, including read length
≥70 bp, mean read quality score ≥25,
low complexity with DUST score ≤7,
ambiguous bases ≤1%, and all duplicates (18). By subtracting the human
reference genome, NCBI reference
sequences for bacteria, viruses and
fungi, and NCBI nt database (6), we
calculated and compared the rates of
unmapped sequencing reads for each
sample amplified by either tdMDA or
regular MDA. Potential gene detection
and differential gene expression (DGE)
between HCV and HCC patients were
analyzed by the TopHat-featureCountedgeR pipelines (23,24). In brief, filtered
reads were mapped in TopHat onto the
annotated human reference genome
(Ensembl GRCh 38.84). Gene-counting
data were summarized at the transcriptlevel from TopHat output in featureCounts (25), followed by DGE analysis
in edgeR with the false discovery rate
(FDR) set at 10%.

Statistical analysis
Except for built-in statistical analyses in
programs such as Cufflinks and edgeR,
other comparisons were done using
the two-tailed Student’s t-test. Data
were expressed as the mean ± SD, and
P < 0.05 was considered statistically
significant.
www.BioTechniques.com
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Data availability
Raw sequence data in fastq format
from the seven HCV and HCC patient
samples was deposited in the NCBI
Sequence Read Archive (SRA) under
the SRA accession no. SRP071026.

Results and discussion
Reagent contamination and TIA are two
major concerns in MDA. While these
issues are negligible when using large
amounts of template, both concerns
become significant shortcomings when
working with low or ultralow amounts
of template (typically <1 ng) since they
compress the product space of target
molecules and/or aggravate qualitative biases (2,6,7,26). While reagent
contamination could be minimized or
even eliminated through the use of
clean enzymes and reagents (27,28),
TIA remains a consistent issue in MDA,
despite many attempts to overcome it.
The current study provides a simple, but
efficient solution in which the use of a
specially designed primer (C28) (Figure
1) eliminates TIA.
In a stepwise optimization process,
we first identified that phi29 DNA
polymerase from Epicentre was considerably free of reagent contamination in
comparison to other enzymes (Supplementary Figure S1). UV treatment of the
Epicentre phi29 DNA polymerase eliminated contamination, but MDA yield was
reduced, while UV treatment of dNTPs
or random hexamer primers abolished
or compromised the reaction (Supplementary Figure S2). In the standard MDA
protocol using the phi29 enzyme from
Epicentre, all additives had no apparent
role in eliminating TIA (Supplementary
Figure S2). Incubation temperatures
>31°C reduced yield, while temperatures <30°C enhanced TIA (Supplementary Figure S2). These results led us
to focus on primer design to eliminate
TIA in MDA.
As expected from the strong 3´→5´
exonuclease activity of phi29 DNA
polymerase, which digests oligonucleotides (29), Primer 6N of the Group 1
primers produced no DNA amplification.
Primers C5 and C6 failed to amplify the
HCV plasmid, while the performance of
Primer C7 was similar to the random
hexamer primer (Primer 6NS2) (Figure
1). Internal modification of the C3 spacer
Vol. 63 | No. 1 | 2017
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Figure 3. Transcriptome sequencing of circulating RNA. (A) RNA extracted from seven patient serum samples was amplified using real-time reverse transcription–template dependent
multiple displacement amplification (RT-tdMDA). Lanes 1–2: negative control (water); Lanes
3–9: seven hepatitis C virus (HCV) and hepatocellular carcinoma (HCC) patient serum samples; M: lambda DNA/HindIII marker. (B) Comparisons of the percentages of unmapped reads
and TopHat mapping rates between tdMDA and regular MDA. (C) Differential gene expression
(DGE) analysis in edgeR identified 457 genes showing ≥2 fold changes either up- (n = 424)
or down-regulation (n = 23) in the HCC group. (D) Unsupervised clustering analysis among
HCV and HCC patients based on the leading log-fold-change of detected gene transcripts.

caused steric hindrance. However, such
hindrance, as shown with the Group 2
primers, cannot differentiate between
self and primer-template priming, which
was not improved by the inclusion of
LNA bases (Group 3). Despite the
theoretical possibility (30), RNA primers
(Group 4) were incapable of inhibiting
TIA. The constrained primers in Group 5
resulted in an overall reduction of MDA
yields, and TIA was still observed.
Substantial suppression of TIA was
found in MDA using 5´ end-blocked
random hexamer (Group 6) or pentamer
(Group 7) primers (Figure 1). Of the
eight options to block 5´ ends of
random pentamer primers, consecutive
dSpacer (1´,2´-dideoxyribose) (Primer
C22), amino modifier C6 (Primer C30)
and hexynyl (Primer C31) produced no
amplification at all. While other options
showed a substantial suppression
of TIA, consistent suppression of
TIA resulting in increased reproducibility was only achieved using the
C18 spacer modification (Primer C28),
suggesting the subtle influence of the
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different blocking options (Figure 1).
Given the decreased melting temperatures of random pentamer primers
in comparison to random hexamer
primers, the incubation temperature
in MDA with the Group 7 primers was
initially reduced from 30°C to 28°C. In
subsequent experiments with Primer
C28, this temperature appeared to be
optimal with regard to the complete
elimination of TIA and provided MDA
yields comparable to the use of the
random hexamer primers with or
without C18 spacer–blocked 5´ ends
(Figure S3).
The tdMDA reaction could tolerate
primer concentrations up to 400 µM
(Supplementary Figure S4). Beyond this
threshold, yield was reduced dramatically, perhaps due to decreased Mg 2+
concentration caused by binding to
primer (31). For HCV plasmid amounts
ranging from 1 ng to 50 pg, tdMDA yields
were maximized with primer concentrations of 80–100 µM. When the input
amount was lower than 50 pg in a 40-µL
reaction, tdMDA required templates to
www.BioTechniques.com
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be freshly prepared. After being resuspended in water, Primer C28 with the
C18 spacer modification was considerably stable. No apparent reduction in
MDA yields was seen when using Primer
C28 subjected to 30 thaw-freeze cycles
(Supplementary Figure S5). Similarly,
tdMDA was reproducible when using
Primer C28 stored up to 6 months at
-20°C (Supplementary Figure S5).
The mechanisms for TIA generation in MDA are not fully understood.
However, based on the observations
from the current study, we speculate
there two possibilities: (i) polymerase
jumping and (ii) self-priming. It has long
been known that Taq DNA polymerase
is capable of jumping among templates
(32). We believe that this kind of activity
might be enhanced by phi29 DNA
polymerase due to the polymerase’s
inability to be used as a molecular brake
in comparison to Taq DNA polymerase
(Sahu, S. PhD thesis, Duke University,
2007). Polymerase jumping among

random primers could form artificial
templates for the generation of TIA. This
process was abolished by blocking the
5´ ends of random primers. On the other
hand, self-priming is thought to be a
common mechanism responsible for
artifacts in PCR and MDA (12). Our data
showed no product was generated in
MDA with Primer C5, which was actually
4-bp in length after digestion owing to
the exonuclease activity of phi29 DNA
polymerase. Thus, efficient polymerization by phi29 DNA polymerase may
require 5-bp priming, which would
potentially allow self-priming among
random hexamer (6 bp) primers. This
may explain why TIA cannot be eliminated entirely through the use of random
hexamer primers with 5´ ends blocked
by the C18 spacer (Figure 1). Primers
C1 and C2 have an internal modification of the C3 spacer that theoretically prevents self-priming. Primer C25
is a random pentamer primer without
modification. The use of these primers

Detecting CRISPR gene
editing events just got
QUICKR
Introducing AccuCleave for use with
agarose gels
• Simple and accurate enzymatic digestion assay
• Reduce sequencing costs and times with
efficient screening methods
• Optimized Taq eliminates time consuming
PCR cleanup
Streamline your genetic editing workflows
at www.aati-us.com/AccuCleave

R

aati-us.com

produces a significant amount of TIA
(Figure 1). Based on these observations,
polymerase jumping, rather than selfpriming, might be the critical factor for
TIA formation in MDA.
Finally, tdMDA was evaluated for
profiling circulating RNA. The average
RNA recover y from 200 µL serum
was 10.76 ± 2.8 ng using the QIAGEN
miRNeasy Serum/Plasma kit. Af ter
optimizing genomic DNA removal
(Supplementary Table S1), 3 serum
samples with various RNA yields were
selected for real-time RT-MDA with a
24-h incubation. While DNA accumulation was not observed in the negative
control (water), amplification of all 3
samples with 10-fold serial dilutions
plateaued after an approximately 18-h
incubation (Figure 2). The protocol
was then applied to the seven HCV
and HCC patient samples (Figure
3A). Illumina sequencing of RT-tdMDA
product provided an average of 1.45
million reads per sample. Unmapped
reads were significantly lower in tdMDA
than regular MDA with random hexamer
primers (7 ± 10.9% versus 58.6 ± 39%; P
= 0.006) (Figure 3B). Data generated via
tdMDA showed a much higher mapping
rate than regular MDA in TopHat (26.9 ±
7.9% versus 5.8 ± 8.2%; P = 3.8 × 10 -4)
(Figure 3B). The TopHat-feature CountsedgeR analysis detected 3459 genes in
human circulating RNA. Of these 3459
genes, 457 showed ≥2 fold changes,
either up- (n = 424) or down-regulated
(n = 23) in the HCC group (Figure
2C). Notably, unsupervised clustering
analysis showed a clear separation of
HCV from HCC based on the leading
log-fold-change, which is the rootmean-square average of the largest
log2-fold-changes between each pair
of samples (Figure 2D) (24).
Here, we repor ted a simple but
reliable solution for the elimination of
TIA in MDA. Template-dependent amplification should extend MDA’s application to biological specimens with low
or ultralow amounts of genetic material.
By applying tdMDA, we demonstrated
that efficient profiling of circulating RNA
can be achieved from as little as 0.2 mL
patient serum. Substantial differences
in transcriptome profiles between HCV
and HCC patients further demonstrate
the promise of tdMDA for RNA-based
liquid biopsy applications.
www.BioTechniques.com
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